The growth of Viagra and its effect on the medicinal landscape presents a complex question for investors. While the early sales figures were impressive, the intellectual property has expired, leading to a flood of copycat alternatives that are eroding earnings. Moreover, the market is facing issues related to population trends and evolving healthca